Actively Recruiting
Extracellular Vesicles and Dysregulated Coagulation in the Prediction of Stroke
Led by Cwm Taf University Health Board (NHS) · Updated on 2024-08-20
360
Participants Needed
1
Research Sites
308 weeks
Total Duration
On this page
Sponsors
C
Cwm Taf University Health Board (NHS)
Lead Sponsor
C
Cardiff Metropolitan University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Annually 100,000 strokes occur, placing stroke as the largest cause of disability in the UK. 90% of strokes are preventable, leading to national focus on programmes including "The National Stroke Programme" to act on preventing, treating, and improving post-stroke care. Importantly, over 25% of ischaemic stroke sufferers have previously had a Transient Ischaemic Attack (TIA), which presents the biggest concern for TIA patients. There are no measures which reliably identify TIA patients most likely to suffer a stroke. Novel biomarkers for predicting stroke are key to addressing this problem. The PREDICT-EV study aims to screen 300 TIA patients and follow them over 12-months. The investigators will determine if a novel biomarker we've identified to increase thrombotic risk (endothelial derived extracellular vesicles) and the resulting increased prothrombin time is associated with patients at highest risk of stroke.
CONDITIONS
Official Title
Extracellular Vesicles and Dysregulated Coagulation in the Prediction of Stroke
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed or suspected of having a Transient Ischaemic Attack (TIA) by a stroke physician
- TIA patients prescribed antiplatelet drugs or anticoagulants
- Patients aged over 18 years
- Patients able to eat an ordinary diet by mouth
- Patients with brain imaging confirming cerebral infarction (stroke) for phase 2
- Stroke caused by embolic, atherothromboembolic, or in-situ thrombosis mechanisms
- Patients not requiring further investigations to confirm stroke diagnosis
- Patients not pregnant or breastfeeding (phase 2)
You will not qualify if you...
- Inability to give consent
- Inability to feed by mouth
- Short life expectancy
- Pregnancy or breastfeeding
- Symptoms explained by medical problems other than focal cerebral ischaemia
- Patients without prior consent for follow-up blood sampling (phase 2)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Prince Charles Hospital
Merthyr Tydfil, United Kingdom, CF479DT
Actively Recruiting
Research Team
J
Jessica Williams, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here